<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;ff=20240221193716&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;ff=20240221193716&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 22 Feb 2024 00:37:17 +0000</lastbuilddate>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Innovative approaches to risk stratification in interventional cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38381944/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 21;45(8):557-560. doi: 10.1093/eurheartj/ehae097.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38381944/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38381944</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae097>10.1093/eurheartj/ehae097</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38381944</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Innovative approaches to risk stratification in interventional cardiology</dc:title>
<dc:identifier>pmid:38381944</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae097</dc:identifier>
</item>
<item>
<title>Interventions for Optimization of Guideline-Directed Medical Therapy: A Systematic Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38381449/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This review summarizes interventions aimed at optimization of GDMT in clinical practice. Initiatives that used interdisciplinary teams, largely comprised of nurses and pharmacists, most consistently led to improvements in GDMT. Additional large, randomized studies are necessary to better understand other types of interventions, as well as their long-term efficacy and sustainability.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 21. doi: 10.1001/jamacardio.2023.5627. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Implementation of guideline-directed medical therapy (GDMT) in real-world practice remains suboptimal. It is unclear which interventions are most effective at addressing current barriers to GDMT in patients with heart failure with reduced ejection fraction (HFrEF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To perform a systematic review to identify which types of system-level initiatives are most effective at improving GDMT use among patients with HFrEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EVIDENCE REVIEW: PubMed, Embase, Cochrane, CINAHL, and Web of Science databases were queried from January 2010 to November 2023 for randomized clinical trials that implemented a quality improvement intervention with GDMT use as a primary or secondary outcome. References from related review articles were also included for screening. Quality of studies and bias assessment were graded based on the Cochrane Risk of Bias tool and Oxford Centre for Evidence-Based Medicine.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">FINDINGS: Twenty-eight randomized clinical trials were included with an aggregate sample size of 19 840 patients. Studies were broadly categorized as interdisciplinary interventions (n = 15), clinician education (n = 5), electronic health record initiatives (n = 6), or patient education (n = 2). Overall, interdisciplinary titration clinics were associated with significant increases in the proportion of patients on target doses of GDMT with a 10% to 60% and 2% to 53% greater proportion of patients on target doses of β-blockers and renin-angiotensin-aldosterone system inhibitors, respectively, in intervention groups compared with usual care. Other interventions, such as audits, clinician and patient education, or electronic health record alerts, were also associated with some improvements in GDMT utilization, though these findings were inconsistent across studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This review summarizes interventions aimed at optimization of GDMT in clinical practice. Initiatives that used interdisciplinary teams, largely comprised of nurses and pharmacists, most consistently led to improvements in GDMT. Additional large, randomized studies are necessary to better understand other types of interventions, as well as their long-term efficacy and sustainability.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38381449/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38381449</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5627>10.1001/jamacardio.2023.5627</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38381449</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Amber B Tang</dc:creator>
<dc:creator>Nicholas K Brownell</dc:creator>
<dc:creator>Jacob S Roberts</dc:creator>
<dc:creator>Amier Haidar</dc:creator>
<dc:creator>Antonia Osuna-Garcia</dc:creator>
<dc:creator>David J Cho</dc:creator>
<dc:creator>Pooya Bokhoor</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Interventions for Optimization of Guideline-Directed Medical Therapy: A Systematic Review</dc:title>
<dc:identifier>pmid:38381449</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5627</dc:identifier>
</item>
<item>
<title>Accelerometer-Measured Physical Activity, Sedentary Time, and Heart Failure Risk in Women Aged 63 to 99 Years</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38381446/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Higher accelerometer-measured PA (MVPA, light PA, steps per day) was associated with lower risk (and greater total sedentary time with higher risk) of overall HF and HFpEF in a racially and ethnically diverse cohort of older women. Increasing PA and reducing sedentary time for primary HFpEF prevention may have relevant implications for cardiovascular resilience and healthy aging in later life.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 21. doi: 10.1001/jamacardio.2023.5692. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Heart failure (HF) prevention is paramount to public health in the 21st century.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine incident HF and its subtypes with preserved ejection fraction (HFpEF) and reduced EF (HFrEF) according to accelerometer-measured physical activity (PA) and sedentary time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a prospective cohort study, the Objective Physical Activity and Cardiovascular Health (OPACH) in Older Women study, conducted from March 2012 to April 2014. Included in the analysis were women aged 63 to 99 years without known HF, who completed hip-worn triaxial accelerometry for 7 consecutive days. Follow-up for incident HF occurred through February 2022. Data were analyzed from March to December 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Daily PA (total, light, moderate to vigorous PA [MVPA], steps) and sedentary (total, mean bout duration) behavior.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Adjudicated incident HF, HFpEF, and HFrEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 5951 women (mean [SD] age, 78.6 [6.8] years) without known HF were included in this analysis. Women self-identified with the following race and ethnicity categories: 2004 non-Hispanic Black (33.7%), 1022 Hispanic (17.2%), and 2925 non-Hispanic White (49.2%). There were 407 HF cases (257 HFpEF; 110 HFrEF) identified through a mean (SD) of 7.5 (2.6) years (range, 0.01-9.9 years) of follow-up. Fully adjusted hazard ratios (HRs) for overall HF, HFpEF, and HFrEF associated with a 1-SD increment were 0.85 (95% CI, 0.75-0.95), 0.78 (95% CI, 0.67-0.91), and 1.02 (95% CI, 0.81-1.28) for minutes per day total PA; 0.74 (95% CI, 0.63-0.88), 0.71 (95% CI, 0.57-0.88), and 0.83 (95% CI, 0.62-1.12) for steps per day; and 1.17 (95% CI, 1.04-1.33), 1.29 (95% CI, 1.10-1.51), and 0.94 (95% CI, 0.75-1.18) for minutes per day total sedentary. Cubic spline curves for overall HF and HFpEF were significant inverse for total PA and steps per day and positive for total sedentary. Light PA and MVPA were inversely associated with overall HF (HR per 1 SD: 0.88; 95% CI, 0.78-0.98 and 0.84; 95% CI, 0.73-0.97) and HFpEF (0.80; 95% CI, 0.70-0.93 and 0.85; 95% CI, 0.72-1.01) but not HFrEF. Associations did not meaningfully differ when stratified by age, race and ethnicity, body mass index, physical function, or comorbidity score. Results for sedentary bout duration were inconsistent.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Higher accelerometer-measured PA (MVPA, light PA, steps per day) was associated with lower risk (and greater total sedentary time with higher risk) of overall HF and HFpEF in a racially and ethnically diverse cohort of older women. Increasing PA and reducing sedentary time for primary HFpEF prevention may have relevant implications for cardiovascular resilience and healthy aging in later life.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38381446/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38381446</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5692>10.1001/jamacardio.2023.5692</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38381446</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Michael J LaMonte</dc:creator>
<dc:creator>Andrea Z LaCroix</dc:creator>
<dc:creator>Steve Nguyen</dc:creator>
<dc:creator>Kelly R Evenson</dc:creator>
<dc:creator>Chongzhi Di</dc:creator>
<dc:creator>Marcia L Stefanick</dc:creator>
<dc:creator>Eric T Hyde</dc:creator>
<dc:creator>Blake Anuskiewicz</dc:creator>
<dc:creator>Charles B Eaton</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Accelerometer-Measured Physical Activity, Sedentary Time, and Heart Failure Risk in Women Aged 63 to 99 Years</dc:title>
<dc:identifier>pmid:38381446</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5692</dc:identifier>
</item>
<item>
<title>Statins, Inflammation, and Tissue Context in REPRIEVE</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38381416/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 21. doi: 10.1001/jamacardio.2023.5671. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38381416/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38381416</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5671>10.1001/jamacardio.2023.5671</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38381416</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Matthew J Feinstein</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Statins, Inflammation, and Tissue Context in REPRIEVE</dc:title>
<dc:identifier>pmid:38381416</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5671</dc:identifier>
</item>
<item>
<title>Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38381407/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In PWH at low to moderate CVD risk, 24 months of pitavastatin reduced noncalcified plaque volume and progression as well as markers of lipid oxidation and arterial inflammation. These changes may contribute to the observed MACE reduction in REPRIEVE.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 21. doi: 10.1001/jamacardio.2023.5661. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Cardiovascular disease (CVD) is increased in people with HIV (PWH) and is characterized by premature noncalcified coronary plaque. In the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), pitavastatin reduced major adverse cardiovascular events (MACE) by 35% over a median of 5.1 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the effects of pitavastatin on noncalcified coronary artery plaque by coronary computed tomography angiography (CTA) and on inflammatory biomarkers as potential mechanisms for MACE prevention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled randomized clinical trial enrolled participants from April 2015 to February 2018 at 31 US clinical research sites. PWH without known CVD who were taking antiretroviral therapy and had low to moderate 10-year CVD risk were included. Data were analyzed from April to November 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Oral pitavastatin calcium, 4 mg per day.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Coronary CTA and inflammatory biomarkers at baseline and 24 months. The primary outcomes were change in noncalcified coronary plaque volume and progression of noncalcified plaque.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 804 enrolled persons, 774 had at least 1 evaluable CTA. Plaque changes were assessed in 611 who completed both CT scans. Of 611 analyzed participants, 513 (84.0%) were male, the mean (SD) age was 51 (6) years, and the median (IQR) 10-year CVD risk was 4.5% (2.6-7.0). A total of 302 were included in the pitavastatin arm and 309 in the placebo arm. The mean noncalcified plaque volume decreased with pitavastatin compared with placebo (mean [SD] change, -1.7 [25.2] mm3 vs 2.6 [27.1] mm3; baseline adjusted difference, -4.3 mm3; 95% CI, -8.6 to -0.1; P = .04; 7% [95% CI, 1-12] greater reduction relative to placebo). A larger effect size was seen among the subgroup with plaque at baseline (-8.8 mm3 [95% CI, -17.9 to 0.4]). Progression of noncalcified plaque was 33% less likely with pitavastatin compared with placebo (relative risk, 0.67; 95% CI, 0.52-0.88; P = .003). Compared with placebo, the mean low-density lipoprotein cholesterol decreased with pitavastatin (mean change: pitavastatin, -28.5 mg/dL; 95% CI, -31.9 to -25.1; placebo, -0.8; 95% CI, -3.8 to 2.2). The pitavastatin arm had a reduction in both oxidized low-density lipoprotein (-29% [95% CI, -32 to -26] vs -13% [95% CI, -17 to -9]; P &lt; .001) and lipoprotein-associated phospholipase A2 (-7% [95% CI, -11 to -4] vs 14% [95% CI, 10-18]; P &lt; .001) compared with placebo at 24 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In PWH at low to moderate CVD risk, 24 months of pitavastatin reduced noncalcified plaque volume and progression as well as markers of lipid oxidation and arterial inflammation. These changes may contribute to the observed MACE reduction in REPRIEVE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02344290.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38381407/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38381407</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5661>10.1001/jamacardio.2023.5661</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38381407</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Michael T Lu</dc:creator>
<dc:creator>Heather Ribaudo</dc:creator>
<dc:creator>Borek Foldyna</dc:creator>
<dc:creator>Markella V Zanni</dc:creator>
<dc:creator>Thomas Mayrhofer</dc:creator>
<dc:creator>Julia Karady</dc:creator>
<dc:creator>Jana Taron</dc:creator>
<dc:creator>Kathleen V Fitch</dc:creator>
<dc:creator>Sara McCallum</dc:creator>
<dc:creator>Tricia H Burdo</dc:creator>
<dc:creator>Kayla Paradis</dc:creator>
<dc:creator>Sandeep S Hedgire</dc:creator>
<dc:creator>Nandini M Meyersohn</dc:creator>
<dc:creator>Christopher DeFilippi</dc:creator>
<dc:creator>Carlos D Malvestutto</dc:creator>
<dc:creator>Audra Sturniolo</dc:creator>
<dc:creator>Marissa Diggs</dc:creator>
<dc:creator>Sue Siminski</dc:creator>
<dc:creator>Gerald S Bloomfield</dc:creator>
<dc:creator>Beverly Alston-Smith</dc:creator>
<dc:creator>Patrice Desvigne-Nickens</dc:creator>
<dc:creator>Edgar T Overton</dc:creator>
<dc:creator>Judith S Currier</dc:creator>
<dc:creator>Judith A Aberg</dc:creator>
<dc:creator>Carl J Fichtenbaum</dc:creator>
<dc:creator>Udo Hoffmann</dc:creator>
<dc:creator>Pamela S Douglas</dc:creator>
<dc:creator>Steven K Grinspoon</dc:creator>
<dc:creator>REPRIEVE Trial Writing Group</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38381407</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5661</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2023: the top 10 papers in valvular heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38380439/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 21:ehae090. doi: 10.1093/eurheartj/ehae090. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38380439/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38380439</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae090>10.1093/eurheartj/ehae090</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38380439</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>David Messika-Zeitoun</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Helmut Baumgartner</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2023: the top 10 papers in valvular heart disease</dc:title>
<dc:identifier>pmid:38380439</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae090</dc:identifier>
</item>
<item>
<title>Surgical or percutaneous treatment of mitral regurgitation: clip or cut?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38379446/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 21:ehae084. doi: 10.1093/eurheartj/ehae084. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38379446/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38379446</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae084>10.1093/eurheartj/ehae084</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38379446</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Karl-Patrik Kresoja</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Surgical or percutaneous treatment of mitral regurgitation: clip or cut?</dc:title>
<dc:identifier>pmid:38379446</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae084</dc:identifier>
</item>
<item>
<title>Anticoagulation in device-detected atrial fibrillation: a long journey to find the sweet spot</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38379436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 21:ehae044. doi: 10.1093/eurheartj/ehae044. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38379436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38379436</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae044>10.1093/eurheartj/ehae044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38379436</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Emma Svennberg</dc:creator>
<dc:creator>Søren Zöga Diederichsen</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Anticoagulation in device-detected atrial fibrillation: a long journey to find the sweet spot</dc:title>
<dc:identifier>pmid:38379436</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae044</dc:identifier>
</item>
<item>
<title>Transcatheter vs. surgical treatment of aortc stenosis: long awaited long-term data, yet a long way to go</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38379271/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Feb 21:ehad873. doi: 10.1093/eurheartj/ehad873. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38379271/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38379271</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad873>10.1093/eurheartj/ehad873</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38379271</guid>
<pubDate>Wed, 21 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Sabine Bleiziffer</dc:creator>
<dc:date>2024-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transcatheter vs. surgical treatment of aortc stenosis: long awaited long-term data, yet a long way to go</dc:title>
<dc:identifier>pmid:38379271</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad873</dc:identifier>
</item>
<item>
<title>Antiplatelet Therapy After PCI: The Art and Science of De-Escalation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377261/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):601-604. doi: 10.1161/CIRCULATIONAHA.123.067767. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377261/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38377261</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067767>10.1161/CIRCULATIONAHA.123.067767</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377261</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Robert F Storey</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Antiplatelet Therapy After PCI: The Art and Science of De-Escalation</dc:title>
<dc:identifier>pmid:38377261</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067767</dc:identifier>
</item>
<item>
<title>Correction to: Addressing Structural Racism Through Public Policy Advocacy: A Policy Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377260/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):e934. doi: 10.1161/CIR.0000000000001216. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377260/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38377260</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001216>10.1161/CIR.0000000000001216</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377260</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Addressing Structural Racism Through Public Policy Advocacy: A Policy Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38377260</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001216</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377259/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):627-632. doi: 10.1161/CIRCULATIONAHA.124.068812. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377259/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38377259</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068812>10.1161/CIRCULATIONAHA.124.068812</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377259</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:38377259</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068812</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18248</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377258/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):e935. doi: 10.1161/CIR.0000000000001215. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377258/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38377258</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001215>10.1161/CIR.0000000000001215</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377258</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18248</dc:title>
<dc:identifier>pmid:38377258</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001215</dc:identifier>
</item>
<item>
<title>Poker and Cardiology: Judging Our Decisions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377257/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):560-561. doi: 10.1161/CIRCULATIONAHA.123.067366. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377257/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38377257</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067366>10.1161/CIRCULATIONAHA.123.067366</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377257</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Marcos F Mills</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Poker and Cardiology: Judging Our Decisions</dc:title>
<dc:identifier>pmid:38377257</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067366</dc:identifier>
</item>
<item>
<title>Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377256/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):635-637. doi: 10.1161/CIRCULATIONAHA.123.065330. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377256/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38377256</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065330>10.1161/CIRCULATIONAHA.123.065330</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377256</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Shea E Hogan</dc:creator>
<dc:creator>Eike Sebastian Debus</dc:creator>
<dc:creator>Mark R Nehler</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Sonia S Anand</dc:creator>
<dc:creator>Eva Muehlhofer</dc:creator>
<dc:creator>Lloyd P Haskell</dc:creator>
<dc:creator>Scott D Berkowitz</dc:creator>
<dc:creator>Rupert M Bauersachs</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD</dc:title>
<dc:identifier>pmid:38377256</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065330</dc:identifier>
</item>
<item>
<title>Cardiovascular Health Care in Low- and Middle-Income Countries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38377254/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):557-559. doi: 10.1161/CIRCULATIONAHA.123.065717. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38377254/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38377254</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065717>10.1161/CIRCULATIONAHA.123.065717</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38377254</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Ana Olga Mocumbi</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Health Care in Low- and Middle-Income Countries</dc:title>
<dc:identifier>pmid:38377254</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065717</dc:identifier>
</item>
<item>
<title>Addressing Barriers to Entry and Retention of Women in Interventional Vascular Specialties With Proposed Solutions: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38375663/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>Representation of women in interventional vascular fields (interventional cardiology, interventional radiology, and vascular surgery) lags behind that in other specialties. With women representing half of all medical school graduates, encouraging parity of women in these fields needs to start in medical school. Barriers to pursuing careers in vascular intervention include insufficient exposure during core clerkships, early mentorship, visibility of women in the field, length of training,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20. doi: 10.1161/CIR.0000000000001210. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Representation of women in interventional vascular fields (interventional cardiology, interventional radiology, and vascular surgery) lags behind that in other specialties. With women representing half of all medical school graduates, encouraging parity of women in these fields needs to start in medical school. Barriers to pursuing careers in vascular intervention include insufficient exposure during core clerkships, early mentorship, visibility of women in the field, length of training, lifestyle considerations, work culture and environment, and concerns about radiation exposure. This scientific statement highlights potential solutions for both the real and perceived barriers that women may face in pursuing careers in vascular intervention, including streamlining of training (as both interventional radiology and vascular surgery have done with a resultant increase in percentage of women trainees), standardization of institutional promotion of women in leadership, and professional and industry partnerships for the retention and advancement of women.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38375663/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38375663</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001210>10.1161/CIR.0000000000001210</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38375663</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>S Elissa Altin</dc:creator>
<dc:creator>Mimmie Kwong</dc:creator>
<dc:creator>Naomi M Hamburg</dc:creator>
<dc:creator>Mark A Creager</dc:creator>
<dc:creator>Subhash Banerjee</dc:creator>
<dc:creator>Lola Oladini</dc:creator>
<dc:creator>Marabel D Schneider</dc:creator>
<dc:creator>Jean Marie Ruddy</dc:creator>
<dc:creator>American Heart Association Council on Peripheral Vascular Disease; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; and Stroke Council</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Addressing Barriers to Entry and Retention of Women in Interventional Vascular Specialties With Proposed Solutions: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38375663</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001210</dc:identifier>
</item>
<item>
<title>Gsα Regulates Macrophage Foam Cell Formation During Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38375634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Gsα activation is enhanced during atherosclerotic progression and increases lipid uptake and foam cell formation. The genetic or chemical inactivation of Gsα inhibit the development of atherosclerosis in mice, suggesting that drugs targeting Gsα may be useful in the treatment of atherosclerosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 20. doi: 10.1161/CIRCRESAHA.123.323156. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Many cardiovascular pathologies are induced by signaling through G-protein-coupled receptors via Gsα (G protein stimulatory α subunit) proteins. However, the specific cellular mechanisms that are driven by Gsα and contribute to the development of atherosclerosis remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: High-throughput screening involving data from single-cell and bulk sequencing were used to explore the expression of Gsα in atherosclerosis. The differentially expression and activity of Gsα were analyzed by immunofluorescence and cAMP measurements. Macrophage-specific Gsα knockout (Mac-Gsα<sup>KO</sup>) mice were generated to study the effect on atherosclerosis. The role of Gsα was determined by transplanting bone marrow and performing assays for foam cell formation, Dil-ox-LDL (oxidized low-density lipoprotein) uptake, chromatin immunoprecipitation, and luciferase reporter assays.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: ScRNA-seq showed elevated <i>Gnas</i> in atherosclerotic mouse aorta's cholesterol metabolism macrophage cluster, while bulk sequencing confirmed increased <i>GNAS</i> expression in human plaque macrophage content. A significant upregulation of Gsα and active Gsα occurred in macrophages from human and mouse plaques. Ox-LDL could translocate Gsα from macrophage lipid rafts in short-term and promote <i>Gnas</i> transcription through ERK1/2 activation and C/EBPβ phosphorylation via oxidative stress in long-term. Atherosclerotic lesions from Mac-Gsα<sup>KO</sup> mice displayed decreased lipid deposition compared with those from control mice. Additionally, Gsα deficiency alleviated lipid uptake and foam cell formation. Mechanistically, Gsα increased the levels of cAMP and transcriptional activity of the cAMP response element binding protein, which resulted in increased expression of CD36 and SR-A1. In the translational experiments, inhibiting Gsα activation with suramin or cpGN13 reduced lipid uptake, foam cell formation, and the progression of atherosclerotic plaques in mice in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Gsα activation is enhanced during atherosclerotic progression and increases lipid uptake and foam cell formation. The genetic or chemical inactivation of Gsα inhibit the development of atherosclerosis in mice, suggesting that drugs targeting Gsα may be useful in the treatment of atherosclerosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38375634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38375634</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323156>10.1161/CIRCRESAHA.123.323156</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38375634</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Chang Ma</dc:creator>
<dc:creator>Yihui Li</dc:creator>
<dc:creator>Mi Tian</dc:creator>
<dc:creator>Qiming Deng</dc:creator>
<dc:creator>Qin Xiaoteng</dc:creator>
<dc:creator>Hanlin Lu</dc:creator>
<dc:creator>Jiangang Gao</dc:creator>
<dc:creator>Min Chen</dc:creator>
<dc:creator>Lee S Weinstein</dc:creator>
<dc:creator>Mei Zhang</dc:creator>
<dc:creator>Peili Bu</dc:creator>
<dc:creator>Jianmin Yang</dc:creator>
<dc:creator>Yun Zhang</dc:creator>
<dc:creator>Cheng Zhang</dc:creator>
<dc:creator>Wencheng Zhang</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Gsα Regulates Macrophage Foam Cell Formation During Atherosclerosis</dc:title>
<dc:identifier>pmid:38375634</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323156</dc:identifier>
</item>
<item>
<title>Heartbeat-induced pressure pulsations in cerebral arteries modulate neuronal activity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38374341/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Feb 19. doi: 10.1038/s41569-024-00999-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38374341/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38374341</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00999-y>10.1038/s41569-024-00999-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38374341</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Heartbeat-induced pressure pulsations in cerebral arteries modulate neuronal activity</dc:title>
<dc:identifier>pmid:38374341</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00999-y</dc:identifier>
</item>
<item>
<title>Weight loss from surgery or drug therapy reduces blood pressure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38374340/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Feb 19. doi: 10.1038/s41569-024-01000-6. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38374340/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38374340</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01000-6>10.1038/s41569-024-01000-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38374340</guid>
<pubDate>Tue, 20 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2024-02-20</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Weight loss from surgery or drug therapy reduces blood pressure</dc:title>
<dc:identifier>pmid:38374340</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01000-6</dc:identifier>
</item>
<item>
<title>Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38367616/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240221193716&amp;v=2.18.0.post9+e462414
      <description>CD4^(+) T cells with latent HIV-1 infection persist despite treatment with antiretroviral agents and represent the main barrier to a cure of HIV-1 infection. Pharmacological disruption of viral latency may expose HIV-1-infected cells to host immune activity, but the clinical efficacy of latency-reversing agents for reducing HIV-1 persistence remains to be proven. Here, we show in a randomized-controlled human clinical trial that the histone deacetylase inhibitor panobinostat, when administered...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 16:S0092-8674(24)00105-3. doi: 10.1016/j.cell.2024.01.037. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CD4<sup>+</sup> T cells with latent HIV-1 infection persist despite treatment with antiretroviral agents and represent the main barrier to a cure of HIV-1 infection. Pharmacological disruption of viral latency may expose HIV-1-infected cells to host immune activity, but the clinical efficacy of latency-reversing agents for reducing HIV-1 persistence remains to be proven. Here, we show in a randomized-controlled human clinical trial that the histone deacetylase inhibitor panobinostat, when administered in combination with pegylated interferon-α2a, induces a structural transformation of the HIV-1 reservoir cell pool, characterized by a disproportionate overrepresentation of HIV-1 proviruses integrated in ZNF genes and in chromatin regions with reduced H3K27ac marks, the molecular target sites for panobinostat. By contrast, proviruses near H3K27ac marks were actively selected against, likely due to increased susceptibility to panobinostat. These data suggest that latency-reversing treatment can increase the immunological vulnerability of HIV-1 reservoir cells and accelerate the selection of epigenetically privileged HIV-1 proviruses.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38367616/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240221193716&v=2.18.0.post9+e462414">38367616</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.037>10.1016/j.cell.2024.01.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38367616</guid>
<pubDate>Sat, 17 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Marie Armani-Tourret</dc:creator>
<dc:creator>Ce Gao</dc:creator>
<dc:creator>Ciputra Adijaya Hartana</dc:creator>
<dc:creator>WeiWei Sun</dc:creator>
<dc:creator>Leah Carrere</dc:creator>
<dc:creator>Liliana Vela</dc:creator>
<dc:creator>Alexander Hochroth</dc:creator>
<dc:creator>Maxime Bellefroid</dc:creator>
<dc:creator>Amy Sbrolla</dc:creator>
<dc:creator>Katrina Shea</dc:creator>
<dc:creator>Theresa Flynn</dc:creator>
<dc:creator>Isabelle Roseto</dc:creator>
<dc:creator>Yelizaveta Rassadkina</dc:creator>
<dc:creator>Carole Lee</dc:creator>
<dc:creator>Francoise Giguel</dc:creator>
<dc:creator>Rajeev Malhotra</dc:creator>
<dc:creator>Frederic D Bushman</dc:creator>
<dc:creator>Rajesh T Gandhi</dc:creator>
<dc:creator>Xu G Yu</dc:creator>
<dc:creator>Daniel R Kuritzkes</dc:creator>
<dc:creator>Mathias Lichterfeld</dc:creator>
<dc:date>2024-02-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a</dc:title>
<dc:identifier>pmid:38367616</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.037</dc:identifier>
</item>





























</channel>
</rss>